BioCentury’s roundup of translational innovations also includes a protein conjugation strategy, a SMURF1 inhibitor for hypertension, and more

BioCentury identifies new CAR T cell designs, ADCs and other modalities, plus 37 preclinical targets for

Plus: ATP extends Aulos’ series A, Solu debuts with platform from GSK, and more

Snapshots from the literature add to the growing picture of next-gen CAR T manipulations that could enhance multiple cancer therapies 

Companies are turning to tumor targeting, IL-15 expression and alternate cell sourcing to boost the potency and longevity of NK cell therapies

Plus: Neuroblastoma approval for BeiGene, priority review for Agios’ mitapivat, Arctic Vision, Vectura, AnaptysBio and more

Two months after a regulatory setback for Athenex’s most advanced pipeline program, the biotech is pivoting further into cell therapy through the acquisition of Kuur, which itself had run into

Kuur’s early clinical NKT cell efficacy data add to a growing body of evidence that cell types beyond effector T cells hold promise as cancer therapies. Kuur Therapeutics, which re-launched and